DWJ 1319Alternative Names: DWJ1319
Latest Information Update: 08 Jul 2015
At a glance
- Originator Daewoong Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cholelithiasis
Most Recent Events
- 01 Apr 2015 Phase-III clinical trials in Cholelithiasis (Prevention) in South Korea (PO)